RT unusual_whales (@unusual_whales)BREAKING: Trump extends China tariff deadline by 90 days, per CNBC ...

💥BREAKING:TRUMP EXTENDS CHINA TARIFF DEADLINE 90 DAYS.BULLISH FOR MARKETS! 🚀 https://t.co/vaOzWQZAaB ...

Trade Policy - US extends China tariff deadline by 90 days [1] Market Impact - Market awaits the actual implementation date of China tariffs [1]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to perform their own research and consider their financial situation before making decisions [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to understand how these instruments work and the associated risks before investing [1].

An employee handles one kilogram gold bullions at the YLG Bullion International Co. headquarters in Bangkok, Thailand, on Friday, Dec. 22, 2023.President Donald Trump said Monday that gold will not face tariffs.Gold futures closed at a record high Friday on reports that the precious metal would face duties. U.S. Customs and Border Protection reportedly said gold bars were not excluded from Trump's reciprocal tariffs. The White House on Friday said it would issue an executive order that clarifies "misinforma ...

💥BREAKING:🇺🇸 TRUMP SAYS GOLD WILL NOT NOT BE TARIFFED. https://t.co/POEJf1ZK0M ...

Trade Relations - Brazilian government is promoting a tariff relief plan [1] - The plan is happening amid discussions with the US Treasury [1] - The goal is to ease trade tensions between Brazil and the US [1]

US Consumers Will Bear the Brunt of Tariff Costs, Goldman Says https://t.co/4liSClfxPD ...

Summary of Conference Call on China Healthcare Sector Industry Overview - The conference call focused on the **China Healthcare** sector, particularly the pharmaceutical industry, amidst concerns regarding potential tariffs from the US on pharmaceutical products and services [1][67]. Key Points and Arguments 1. **Tariff Concerns**: The US announced a ~100% tariff on semiconductor chips, which has negatively impacted market sentiment regarding upcoming pharmaceutical tariffs [2][8]. 2. **Low Likelihood of Tariffs on BD Deal Payments**: The analysis suggests a low probability of tariffs being imposed on out-licensing deal payments, as US tariffs have primarily targeted tangible goods rather than service-related income [3][8]. 3. **Focus on Manufacturing Rights**: Most business development (BD) agreements grant manufacturing rights to licensors, with some companies like Pfizer planning to manufacture licensed products in the US [3][8]. 4. **Expectations for Future BD Deals**: There is an expectation for an increase in BD deals in the second half of 2025, particularly from key pharmaceutical companies with robust pipelines such as Hengrui, Hansoh, Sino Biopharma, and CSPC [4][8]. 5. **Minimal Impact of Tariffs**: Chinese pharmaceutical companies have low exposure to finished drug sales in the US, indicating that any potential tariffs would likely have a minimal immediate impact [4][8]. Additional Important Insights - **Market Reaction**: The Hang Seng Healthcare index experienced a 3% decline during the trading session, attributed to profit-taking and concerns over US pharmaceutical tariffs [8]. - **Service Trade Surplus**: The US maintains a services trade surplus with China, which may further reduce the likelihood of tariffs on service-related income, including intellectual property transfers [3][8]. - **Exhibit Data**: An exhibit presented data showing that most Chinese pharmaceutical companies have minimal overseas sales contributions, reinforcing the argument that tariffs would not significantly affect their operations [11][12]. Conclusion - The overall sentiment regarding the China Healthcare sector remains **attractive**, with expectations for continued growth in business development activities despite tariff concerns [5][67].

New Zealand Prime Minister Christopher Luxon has conceded the government is unlikely to win a reduction in the tariff rate the US has applied to New Zealand goods https://t.co/XCZs5CPwuh ...